What is Cagrilintide?

Cagrilintide is an investigational long-acting amylin analogue peptide studied for its potential role in appetite regulation, satiety signaling, and body composition management.

It mimics amylin, a naturally occurring hormone released alongside insulin that helps regulate:

• hunger
• gastric emptying
• glucose balance
• meal size

Because modern diets and metabolic dysfunction may blunt natural amylin signaling, synthetic analogues like cagrilintide are being explored for their ability to restore satiety cues and reduce caloric intake.

It is frequently researched alone or in combination with GLP-1 compounds for complementary metabolic effects.

How It Works

Cagrilintide appears to influence appetite and metabolism through several mechanisms:

• Satiety signaling – promotes earlier “fullness” during meals
• Delayed gastric emptying – slows digestion to prolong satiety
• Reduced food intake – may naturally lower calorie consumption
• Glucose regulation support – works alongside insulin pathways
• Energy balance effects – associated with fat mass reduction in research settings

Unlike stimulatory compounds, amylin-based peptides primarily act through hormonal appetite control, not increased metabolic stress.

Note: Evidence comes from clinical and metabolic research. Long-term outcomes continue to be studied.

Forms & Delivery Methods

Cagrilintide is typically studied via:

• Subcutaneous research injection
• Once or twice weekly administration

Its extended half-life allows for sustained appetite-regulating effects without daily dosing.

Systemic delivery is required to influence hormonal signaling.

Typical Dosing Guidance (Research Context Only)

Sources: peptide education resources and clinical research summaries

As an investigational compound, there are no approved dosing standards.

Common research approaches include:

• 0.3–2.4 mg weekly ranges
• gradual titration to improve tolerance
• protocols commonly spanning 8–20+ weeks

Lower starting doses are often used to minimise gastrointestinal discomfort.

Important: Dosing reflects experimental research practices — not medical prescriptions.

Typical Uses & Applications

Appetite Regulation Research

Studied for hunger control and reduced meal size.

Body Composition Protocols

Investigated for fat mass reduction through caloric intake control.

Metabolic Health Support

Explored for improved glucose handling and insulin synergy.

Stack Protocols

Often paired with GLP-1 or dual/triple agonists (e.g., tirzepatide or retatrutide) for complementary effects.

Safety & Side Effects

Commonly discussed effects may include:

• nausea
• decreased appetite
• mild gastrointestinal discomfort
• fullness or bloating sensations
• injection site irritation

Side effects are typically dose-dependent and may lessen with gradual titration.

Human safety research is ongoing.

Regulatory & Evidence Context

Cagrilintide is an investigational compound and has not been approved by major health authorities for therapeutic use.

Its use remains limited to laboratory, educational, and clinical research settings.

Regenix Quality Commitment

• Purity verified via HPLC
• Traceable sourcing
• Small batch oversight
• Laboratory-grade research compounds only

Important Notice

Supplied strictly for laboratory research and educational purposes only.
Not for human consumption or medical use.